Physicochemical Properties
| Molecular Formula | C10H9N4NAO2S |
| Molecular Weight | 272.2588 |
| Exact Mass | 272.034 |
| CAS # | 547-32-0 |
| Related CAS # | Sulfadiazine;68-35-9;Sulfadiazine-d4;1020719-78-1 |
| PubChem CID | 15899898 |
| Appearance | White to off-white solid powder |
| Density | 1.496g/cm3 |
| Boiling Point | 512.6ºC at 760 mmHg |
| Flash Point | 263.8ºC |
| LogP | 2.38 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 18 |
| Complexity | 332 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | JLDCNMJPBBKAHH-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C10H9N4O2S.Na/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1 |
| Chemical Name | sodium;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | This study assessed the efficacy of pyrimethamine and sodium sulfadiazine in treating mice infected with various atypical Toxoplasma gondii during an acute infection. A total of seven strains of Toxoplasma gondii were injected into Swiss mice. Treatment for the infected mice involved giving them 10-640 mg/kg of sodium sulfadiazine, 3-200 mg/kg of pyrimethamine, or a less potent combination of the two medications every day. The relationship between genotype and sensitivity to sodium and/or pyrimethamine was assessed using descriptive analysis. Treatment with salt or pyrimethamine decreased the sensitivity of the TgCTBr4 and TgCTBr17 strains (genotype 108). Similar sensitivity to PYR was seen in TgCTBr1 and TgCTBr25 strains (genotype 206), but not in response to salt treatment. The only strain that responds well to treatment with both medications is the TgCTBr9 strain (genotype 11) [1]. |
| References |
[1]. Abundance and transferability of antibiotic resistance as related to the fate of sulfadiazine in maize rhizosphere and bulk soil. FEMS Microbiol Ecol. 2013 Jan;83(1):125-34. [2]. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil. Exp Parasitol. 2019 Jul;202:7-14. |
| Additional Infomation |
Sulfadiazine Sodium is a sodium salt form of sulfadiazine, an intermediate-acting bacteriostatic, synthetic sulfanilamide derivative. See also: Sulfadiazine (has active moiety); Pyrimethamine; Sulfadiazine Sodium (component of); Sulfadiazine Sodium; Trimethoprim (component of). |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~459.12 mM) H2O : ~100 mg/mL (~367.30 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6730 mL | 18.3648 mL | 36.7296 mL | |
| 5 mM | 0.7346 mL | 3.6730 mL | 7.3459 mL | |
| 10 mM | 0.3673 mL | 1.8365 mL | 3.6730 mL |